The Research Group’s Objectives and Strategy

  1. Acute revascularization therapy: Our research focuses on endovascular intervention. Oslo University Hospital is the largest intervention center in Norway. In cooperation with the neuroradiologist we are doing prospective studies to develop this treatment option further and explore the clinical outcome of endovascular intervention in acute ischemic stroke patients in relation to logistics, clinical and radiological selection. We are also doing analyses of the costs, quality of life and functional level in patients treated with endovascular intervention. In cooperation with the prehospital services we are studying the effect of prehospital selection.The center is also participating in large international RCTs such as

  2. The Nordic Atrial Fibrillation and Stroke Study (NOR-FIB)  We are leading an international prospective multi-center study with long term rhythm monitoring and biomarkers to explore the impact of atrial fibrillation in patients with cryptogenic stroke.  The inclusion phase closes in 2020 and the follow-up phase will be completed in 2021.

  3. Brain health in atrial fibrillation: Patients with atrial fibrillation have an increased risk of stroke, cognitive decline and premature death. Even in the absence of clinical stroke, people with incident AF are likely to reach thresholds of cognitive impairment or dementia at earlier ages than people with no history of AF. We are exploring the impact of inflammation and fibrosis on the risk of stroke, cognitive impairment and AF recurrence in patients with atrial fibrillation in a prospective study that uses advanced technology with 18F-FDG-PET, MRI and biomarkers.
    The European Cerebrovascular Research Infrastructure: Anne Hege Aamodt is the manager of a cerebrovascular research infrastructure with a separate biobank and several ongoing multi-center studies and collaborators in all health regions in Norway and Scandinavia.

  4. Vision and Stroke. The TenCRAOS study Tenecteplase in Central Retinal Artery Occlusion (TenCRAOS): A prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation) is starting in October 2020 with participating centres in all 4 Norwegian health regions and several European countries including Denmark, Sweden, Finland, Belgium, Ireland, Lithuania and Portugal.
    Aamodt is also a member in the Visual impairment in stroke project, NorVIS,

  5. The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19 NeuroCOVID
    The NeuroCOVID study is an prospective observational multi-center study of neurological, neuropsychological and neuropsychiatric manifestations in patients with COVID-19. The project is a multidisciplinary collaboration between infection specialists, neurologists, neuropsychiatrists, neuropsychologists, anesthesiologist, radiologists, neurophysiologists and researchers and is coordinated with the NeuroCOVID initiative in the European Academy of Neurolog (EAN) and the EAN Neuro-covid ReGistrY (ENERGY).

  6. Aamodt is also Chief consultant of the Headache Clinic at Oslo University Hospital and is participating in several headache projects, as the MiBlock study, BASIC study and the OptiMig study. 
Page visits: 265